Interpretation of long-term overall survival from the PRODIGE 23 study. Letter to the Editor regarding 'Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial', by T. Conroy et al

Affiliations

• ¹ Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa. Electronic address: robertomoretto8468@gmail.com.
• ² Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa.
• ³ Department of Oncology, University of Turin, Città della Salute e della Scienza di Torino, Turin, Italy.